Gillian McGovern, Associate Editor

The study authors note that additional policies to reduce structural stigma against sexual minorities could continue to improve the rate of individuals who initiate PrEP use.

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

Further research of these mechanisms could be significant in developing future strategies to disrupt the viral persistence in individuals living with HIV.

The study also showcases a significant decline in asthma mortality rates in China, which were previously higher than the United States from 1990 to 2019.

According to the authors, current HIV care methods demonstrate that the mean age at death for Black MSM was 68.8 years, whereas the mean age for White MSM was 75.6 years.

These findings could make a significant difference in treating patients with Barth syndrome, which is an incurable genetic disease.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.

This innovation could be useful for optimizing the collaboration between patients with asthma and their health care providers through remote telemedicine consultations.

The study authors are encouraged by the findings, noting that LIMS with algorithmic-based classification can aid in early and accurate diagnosis of skin cancer, improving patient prognosis.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

This FDA clearance comes about 11 months after another clearance for appliances to treat mild-to-moderate obstructive sleep apnea (OSA)—the first clearance for oral appliances to treat OSA with supplemental therapies.

Combination prevention strategies reduced the number of new HIV infections among gay and bisexual men who have sex with men; however, improvement of current methods is needed to meet the 2025 and 2030 reduction goals.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

The finding indicates that a potential vaccine can trigger a permanent response in individuals living with HIV-1.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

A change in recurrence-free survival was also observed, with an 89% rate at 24 months in patients who achieved a complete pathologic response.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.

Study results indicate that outcomes were worse among those who inject illicit drugs and Black patients living with HIV.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

The review comes after phase 3 trial results that indicate an improvement in overall survival and progression-free survival, reducing the risk of disease progression and death.

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

Despite patients and clinicians preferring in-person consultations, most patients reported that clinicians answered all questions and effectively resolved issues during remote consultations.

Study investigators found that health care professionals who were assigned male at birth and practiced in the Western region of the United States were more likely to prescribe PrEP to this high-risk population.

The acceptance comes after results from TRANSCEND CLL 004, which is the first trial to demonstrate clinical benefit with a CAR T cell therapy in patients who were previously treated for CLL or SLL.

Not only is the test significant for identifying HIV and TB, but it can be safer for patients living with HIV due to their suppressed immune systems.

In addition to language barriers, pharmacy translation software errors may cause further complications when filling patient prescriptions.

The study also found that 82% of the surveyed physicians reported not getting labs to help determine treatment options for their patients.

A single infusion of VERVE-101, a gene editing tool, improved both blood PCSK9 protein levels and blood LDL-C levels in 10 individuals with high-risk HeFH.

Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.